DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.
2014 Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G.
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
1998 DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R.
Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.
1996 Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P.
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar
A technique for using neural network analysis to perform survival analysis of censored data.
1994 DE LAURENTIIS, Michelino; P. M., Ravdin
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.
2003 DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
2011 Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
2005 DE LAURENTIIS, Michelino; Cancello, G; Zinno, L; Montagna, E; Malorni, L; Esposito, A; Pennacchio, R; Silvestro, L; Giuliano, Mario; Giordano, A; Caputo, F; Accurso, A; DE PLACIDO, Sabino
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
Survival Analysis by means of a novel Neural Network Model
2003 Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA
2000 Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A.
2000 Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
2004 DE PLACIDO, Sabino; Scambia, G; DI VAGNO, G; Naglieri, E; Lombardi, Av; Biamonte, R; Marinaccio, M; Carteni, G; Manzione, L; Febbraro, A; DE MATTEIS, A; Gasparini, G; Valerio, Mr; Danese, S; Perrone, F; Lauria, Rossella; DE LAURENTIIS, Michelino; Greggi, S; Gallo, C; Pignata, S.
Survival analysis of censored data: neural network analysis detection of complex interactions between variables.
1994 DE LAURENTIIS, Michelino; P. M., Ravdin
External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life.
2003 DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. | 1.1 Articolo in rivista | 2014 | Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G. | |
| c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. | 1.1 Articolo in rivista | 1998 | DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R. | |
| Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | 1.1 Articolo in rivista | 2005 | Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. | 1.1 Articolo in rivista | 1996 | Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P. | |
| Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar | |
| A technique for using neural network analysis to perform survival analysis of censored data. | 1.1 Articolo in rivista | 1994 | DE LAURENTIIS, Michelino; P. M., Ravdin | |
| Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. | 1.1 Articolo in rivista | 2003 | DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino | |
| Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. | 1.1 Articolo in rivista | 2011 | Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm | |
| EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Cancello, G; Zinno, L; Montagna, E; Malorni, L; Esposito, A; Pennacchio, R; Silvestro, L; Giuliano, Mario; Giordano, A; Caputo, F; Accurso, A; DE PLACIDO, Sabino | |
| Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco | |
| Survival Analysis by means of a novel Neural Network Model | 1.1 Articolo in rivista | 2003 | Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
| NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA | 1.1 Articolo in rivista | 2000 | Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. | 1.1 Articolo in rivista | 2000 | Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo | |
| Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. | 1.1 Articolo in rivista | 2004 | DE PLACIDO, Sabino; Scambia, G; DI VAGNO, G; Naglieri, E; Lombardi, Av; Biamonte, R; Marinaccio, M; Carteni, G; Manzione, L; Febbraro, A; DE MATTEIS, A; Gasparini, G; Valerio, Mr; Danese, S; Perrone, F; Lauria, Rossella; DE LAURENTIIS, Michelino; Greggi, S; Gallo, C; Pignata, S. | |
| Survival analysis of censored data: neural network analysis detection of complex interactions between variables. | 1.1 Articolo in rivista | 1994 | DE LAURENTIIS, Michelino; P. M., Ravdin | |
| External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino |